Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Rybrevant
Amivantamab is a bispecific antibody that targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) proteins. It is used to treat non-small cell lung cancer (NSCLC) in adults with specific mutations. It is classified as a targeted therapy and a monoclonal antibody.
Amivantamab is used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
Outcome:
Increased risk of torsades de pointes
Mechanism:
Additive QT prolongation
Outcome:
Increased risk of bleeding
Mechanism:
Platelet inhibition
Outcome:
Decreased amivantamab absorption
Mechanism:
Chelation
Most likely new formulation: Subcutaneous injection (2025, 60% confidence)
Based on current clinical trial data and increasing usage, there is a 70% likelihood of amivantamab expanding to other EGFR/MET driven cancers.
Bispecific monoclonal antibody, Antineoplastic agent, EGFR/MET inhibitor
Monoclonal antibody